Rapid assessment of myocardial scar and viability in ischemic heart disease: a cardiovascular magnetic resonance study
© Locca et al; licensee BioMed Central Ltd. 2009
Published: 28 January 2009
One important use of Cardiovascular Magnetic Resonance (CMR) is to visualize the extent of myocardial infarction. Inversion recovery preparation with segmented gradient echo readout (IR-GRE) is considered the gold standard sequence for the detection of late gadolinium enhancement to visualise myocardial infarction. However this technique requires multiple breath-holds and is time consuming. A reliable single shot readout multislice inversion recovery imaging sequence would permit rapid viability imaging improving scanning efficiency.
The aim of this study was to compare the diagnostic accuracy of the multislice single shot SSFP inversion recovery sequence (IR-SSFP) against multiple breath-hold IR-GRE images in detecting the presence or absence of late enhancement.
We studied 86 consecutive patients undergoing a CMR viability assessment. Images were acquired 10 minutes following intravenous injection of 0.1 mmol/Kg gadolinium-DTPA.
Images were analyzed by two blinded observers for the presence or absence of late myocardial enhancement. Both techniques identified the presence of myocardial infarction in 21 patients. Interobserver variability was -1.370 (CI -11.327 to 8.588) for GRE and -1.707 (CI -9.849 to 6.435) for SSFP. The coefficient of repeatability was 42.54 fro GRE and 41.94 for SSFP. The interobserver agreement in the estimate of viability was 0.84 (0.11) for GRE and 0.95 (0.11) for SSPF technique.
Despite its lower spatial resolution, the IR-SSFP single shot multislice imaging sequence was equally capable of detecting the presence or absence of late enhancement compared to the single slice GRE sequence. Clinically, the IR-SSFP sequence can be used to perform a rapid assessment of the presence or absence of late myocardial enhancement to determine myocardial scar and viability.
This article is published under license to BioMed Central Ltd.